UniPharma Co., Ltd.
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and f… Read more
UniPharma Co., Ltd. (6621) - Net Assets
Latest net assets as of June 2025: NT$251.24 Million TWD
Based on the latest financial reports, UniPharma Co., Ltd. (6621) has net assets worth NT$251.24 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$291.61 Million) and total liabilities (NT$40.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$251.24 Million |
| % of Total Assets | 86.16% |
| Annual Growth Rate | -6.62% |
| 5-Year Change | -24.86% |
| 10-Year Change | N/A |
| Growth Volatility | 8.87 |
UniPharma Co., Ltd. - Net Assets Trend (2019–2024)
This chart illustrates how UniPharma Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for UniPharma Co., Ltd. (2019–2024)
The table below shows the annual net assets of UniPharma Co., Ltd. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$284.75 Million | -8.93% |
| 2023-12-31 | NT$312.67 Million | +3.11% |
| 2022-12-31 | NT$303.24 Million | +1.91% |
| 2021-12-31 | NT$297.57 Million | -21.48% |
| 2020-12-31 | NT$378.98 Million | -5.54% |
| 2019-12-31 | NT$401.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to UniPharma Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9495200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$355.01 Million | 124.67% |
| Other Components | NT$34.20 Million | 12.01% |
| Total Equity | NT$284.75 Million | 100.00% |
UniPharma Co., Ltd. Competitors by Market Cap
The table below lists competitors of UniPharma Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
$10.99 Million |
|
Silvair Inc
WAR:SVRS
|
$11.00 Million |
|
Pelangio Exploration Inc
PINK:PGXPF
|
$11.00 Million |
|
Jaya Agra Wattie Tbk
JK:JAWA
|
$11.00 Million |
|
FuelPositive Corp
OTCQB:NHHHF
|
$10.99 Million |
|
AMJ Global Technology
PINK:AMJT
|
$10.99 Million |
|
Arcure SA
PA:ALCUR
|
$10.99 Million |
|
Mega Manunggal Property TBK PT
JK:MMLP
|
$10.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in UniPharma Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 312,673,000 to 284,752,000, a change of -27,921,000 (-8.9%).
- Net loss of 24,819,000 reduced equity.
- Other comprehensive income decreased equity by 34,117,000.
- Other factors increased equity by 31,015,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-24.82 Million | -8.72% |
| Other Comprehensive Income | NT$-34.12 Million | -11.98% |
| Other Changes | NT$31.02 Million | +10.89% |
| Total Change | NT$- | -8.93% |
Book Value vs Market Value Analysis
This analysis compares UniPharma Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.15x to 1.64x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$11.39 | NT$13.15 | x |
| 2020-12-31 | NT$10.77 | NT$13.15 | x |
| 2021-12-31 | NT$8.45 | NT$13.15 | x |
| 2022-12-31 | NT$8.55 | NT$13.15 | x |
| 2023-12-31 | NT$8.81 | NT$13.15 | x |
| 2024-12-31 | NT$8.02 | NT$13.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently UniPharma Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26.56%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.16x
- Recent ROE (-8.72%) is above the historical average (-10.61%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -6.24% | -16.23% | 0.34x | 1.14x | NT$-65.17 Million |
| 2020 | -14.61% | -39.93% | 0.33x | 1.10x | NT$-93.25 Million |
| 2021 | -25.00% | -70.60% | 0.30x | 1.17x | NT$-104.16 Million |
| 2022 | -2.13% | -5.03% | 0.39x | 1.10x | NT$-36.77 Million |
| 2023 | -6.98% | -21.13% | 0.29x | 1.12x | NT$-53.08 Million |
| 2024 | -8.72% | -26.56% | 0.28x | 1.16x | NT$-53.29 Million |
Industry Comparison
This section compares UniPharma Co., Ltd.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,528,453,600
- Average return on equity (ROE) among peers: 3.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| UniPharma Co., Ltd. (6621) | NT$251.24 Million | -6.24% | 0.16x | $10.99 Million |
| Grape King Bio Ltd (1707) | $11.79 Billion | 12.28% | 0.30x | $413.97 Million |
| Standard Chemical & Pharmaceutical Co Ltd (1720) | $8.14 Billion | 10.26% | 0.37x | $160.24 Million |
| Maywufa Co Ltd (1731) | $2.11 Billion | 8.22% | 0.51x | $41.33 Million |
| Allied Biotech Corporation (1780) | $1.17 Billion | 8.33% | 0.78x | $47.92 Million |
| ScinoPharm Taiwan Ltd (1789) | $9.38 Billion | 5.16% | 0.21x | $180.77 Million |
| GeneFerm Biotechnology Co Ltd (1796) | $396.19 Million | 1.14% | 1.48x | $24.30 Million |
| Easywell Biomedicals Inc. (1799) | $696.90 Million | -39.00% | 0.68x | $62.14 Million |
| LIWANLI Innovation Co Ltd (3054) | $799.59 Million | 4.48% | 0.55x | $49.55 Million |
| YungShin Global Holding Corp (3705) | $4.70 Billion | 6.21% | 0.18x | $292.12 Million |
| TTY Biopharm Co Ltd (4105) | $6.11 Billion | 22.00% | 0.56x | $486.74 Million |